Compare IMOS & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMOS | CGEM |
|---|---|---|
| Founded | 1997 | 2016 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 671.7M |
| IPO Year | N/A | 2021 |
| Metric | IMOS | CGEM |
|---|---|---|
| Price | $33.60 | $10.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | 14.4K | ★ 1.1M |
| Earning Date | 02-24-2026 | 02-26-2026 |
| Dividend Yield | ★ 1.99% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $748,307,671.00 | N/A |
| Revenue This Year | $5.78 | N/A |
| Revenue Next Year | $10.84 | N/A |
| P/E Ratio | $157.30 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.78 | $5.68 |
| 52 Week High | $32.51 | $13.33 |
| Indicator | IMOS | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 71.69 | 56.55 |
| Support Level | $29.70 | $9.41 |
| Resistance Level | $30.56 | $10.70 |
| Average True Range (ATR) | 0.60 | 0.60 |
| MACD | 0.27 | -0.05 |
| Stochastic Oscillator | 95.55 | 79.64 |
ChipMOS TECHNOLOGIES Inc is engaged in the research, development, manufacturing, and sale of high-integration and high-precision integrated circuits and related assembly and testing services. The company's segments include Testing, Assembly, Testing, and Assembly for LCD, OLED, and other Display Panel Driver Semiconductors (LCDD), Bumping, and others. It derives a majority of its revenue from Taiwan followed by Japan, the People's Republic of China, Singapore, and others.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.